A clinical trial for frontotemporal dementia with GRN mutations
AVIADOBIO: CHASING CURES. DELIVERING HOPE.™
At AviadoBio, we are relentlessly chasing cures by developing and translating groundbreaking science and precision delivery into potentially life-changing medicines across neurodegenerative diseases, beginning with frontotemporal dementia (FTD).
ASPIRE-FTD is a Phase 1/2 open-label, multi-center study designed to evaluate the safety and preliminary efficacy of AVB-101 in patients with FTD-GRN.
AVB-101 is administered using a neurosurgical procedure directly to the thalamus at expert neurosurgical centers throughout Europe and the United States.
AVB-101 is an investigational one-time therapy designed to deliver a functional copy of the GRN gene directly to the brain, thereby potentially restoring progranulin levels and stopping disease progression in patients with FTD-GRN.
Eligible participants must be 30-75 years old, diagnosed with FTD-GRN (confirmed with a genetic test) and have a caregiver who is able to support them (including attending study visits) for the duration of the study (5 years and 3 months).
There are other criteria that determine eligibility, which may be discussed with a healthcare provider.
AviadoBio policy on expanded access to investigational therapies
Contact us
You can contact us by phone or via email.
US/International
+1 (888) 591 8117
UK
